Akebia Therapeutics (AKBA) Debt to Equity (2018 - 2025)
Historic Debt to Equity for Akebia Therapeutics (AKBA) over the last 8 years, with Q3 2025 value amounting to $1.15.
- Akebia Therapeutics' Debt to Equity rose 25052.09% to $1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.15, marking a year-over-year increase of 25052.09%. This contributed to the annual value of -$0.79 for FY2024, which is 3062.91% up from last year.
- Akebia Therapeutics' Debt to Equity amounted to $1.15 in Q3 2025, which was up 25052.09% from $1.61 recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Debt to Equity peaked at $12.63 during Q4 2022, and registered a low of -$2.63 during Q1 2023.
- Moreover, its 5-year median value for Debt to Equity was $0.45 (2021), whereas its average is $0.85.
- In the last 5 years, Akebia Therapeutics' Debt to Equity soared by 85942.7% in 2022 and then plummeted by 244218.77% in 2023.
- Quarter analysis of 5 years shows Akebia Therapeutics' Debt to Equity stood at $1.32 in 2021, then surged by 858.6% to $12.63 in 2022, then tumbled by 108.98% to -$1.13 in 2023, then soared by 30.63% to -$0.79 in 2024, then skyrocketed by 245.6% to $1.15 in 2025.
- Its Debt to Equity was $1.15 in Q3 2025, compared to $1.61 in Q2 2025 and $1.89 in Q1 2025.